India, April 16 -- Cipla Technologies LLC, a subsidiary of Cipla Limited along with its subsidiaries, affiliates and joint ventures, hereafter together referred to as "Cipla") and Pulmatrix, Inc. (NASDAQ: PULM; hereafter referred to as "Pulmatrix"), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in respiratory disease, today announced their entry into a Definitive Agreement for the co-development and commercialization of Pulmazole (PUR1900) - an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.
Following the Definitive Agreement, Cip Tec will make an upfront payment of ...